Figure 1.
Characterization and quantification of MDCs and PDCs. (A) PBMCs isolated from individuals with pancreatic duct adenocarcinoma (PDAC) (1 week pre surgery) and healthy age matched volunteers were analyzed for MDCs and PDCs levels by flow cytometry. The PBMCs stained with different direct conjugated mabs to distinguish the MDC and PDC from the rest of the cells. The gating was set to exclude debris (R1) and second gate (R2) was set on Lineage (FITC) negative and HLA DR (PerCP) positive cells. The MDCs were identified as Lin-HLA DR+ CD11c+ cells (R3) and PDCs as Lin-HLA DR+ CD123+ cells (R4). Top panel shows the dot plots from a healthy volunteer and the bottom panel shows the dot plots from an individual with PDAC. (B) Percentage of MDCs (top panel) and PDCs (lower panel) prior tumor resection in healthy controls, PDAC, none resectable pancreatic tumor (NRPT), billary duct adenocarcinoma (BDAC), ampullary carcinoma (AC), endocrine carcinoma (EC), and chronic pancreatitis (CP). (C) Correlation of MDC and PDCs numbers (% out of PBMCs) between controls and PDAC. Control: Solid line and black circles r2 = 0.50. PDAC: striped line and white circles r2 = 0.098. Statistically significant differences between individuals with pancreatic disease and healthy controls are indicated as; * = p < 0.05, ** = p < 0.005, *** = p < 0.001